What is da EPOCH R?

What is da EPOCH R?

An abbreviation for a chemotherapy combination used to treat certain types of non-Hodgkin lymphoma. It includes the drugs etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), and rituximab.

What are the side effects of R EPOCH?

Nausea, vomiting, constipation, diarrhea, loss of appetite, pain in belly. Increased appetite and weight gain in the belly, face, back and shoulders. Sores in mouth.

How is R EPOCH administered?

lifestyle, and concerns. R-EPOCH is usually administered over several days rather than getting each medication all at once on a single infusion day. R-EPOCH may be given as entirely inpatient, or as an outpatient sent home with a continuous chemo pump.

How often is R EPOCH given?

DA-EPOCH-R is typically repeated every 21 – 28 days. This is known as one Cycle. Each cycle may be repeated up to 8 times, depending upon the stage of the disease.

What are the results of DA-EPOCH-R phase 2 study?

Despite the limitations of the phase 2 study and the retrospective study, these findings suggest that DA-EPOCH-R is a therapeutic advance for this type of lymphoma. Our results suggest that rituximab significantly improves the outcome of chemotherapy in patients with primary mediastinal B-cell lymphoma.

How many cycles of DA-EPOCH-R do you need?

Patients received chemotherapy consisting of DA-EPOCH-R with filgrastim for 6 to 8 cycles. 17,18 Disease sites were evaluated after cycles 4 and 6. Patients with a reduction of more than 20% in the greatest diameter of their tumor masses between cycles 4 and 6 received 8 cycles of treatment.

When to discontinue DA-EPOCH-R in primary care?

Patients with a reduction of 20% or less between cycles 4 and 6 discontinued therapy after 6 cycles. The method of administering the DA-EPOCH-R is summarized in the Supplementary Appendix (available at NEJM.org).

Which is better EPOCH-R or R-CHOP?

Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma.

About the Author

You may also like these